| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prenatal Exposure Delayed Effects | 73 | 2026 | 650 | 14.490 |
Why?
|
| Diabetes Mellitus, Type 2 | 190 | 2026 | 2578 | 13.550 |
Why?
|
| Adiposity | 57 | 2026 | 532 | 12.820 |
Why?
|
| Diabetes Mellitus, Type 1 | 212 | 2026 | 3918 | 12.740 |
Why?
|
| Diabetes, Gestational | 41 | 2026 | 305 | 9.660 |
Why?
|
| Body Mass Index | 108 | 2026 | 2437 | 8.250 |
Why?
|
| Pediatric Obesity | 42 | 2026 | 637 | 7.700 |
Why?
|
| Birth Weight | 48 | 2026 | 513 | 7.400 |
Why?
|
| Pregnancy | 198 | 2026 | 7182 | 6.600 |
Why?
|
| Maternal Exposure | 31 | 2026 | 188 | 6.060 |
Why?
|
| Child | 327 | 2026 | 22670 | 5.380 |
Why?
|
| Body Composition | 24 | 2023 | 690 | 5.330 |
Why?
|
| Diet | 37 | 2026 | 1277 | 4.990 |
Why?
|
| Insulin Resistance | 37 | 2025 | 1244 | 4.850 |
Why?
|
| Environmental Pollutants | 20 | 2026 | 138 | 4.810 |
Why?
|
| Adolescent | 291 | 2026 | 22479 | 4.590 |
Why?
|
| Cardiovascular Diseases | 48 | 2025 | 2183 | 4.470 |
Why?
|
| Obesity | 73 | 2025 | 3097 | 4.420 |
Why?
|
| Infant, Newborn | 126 | 2026 | 6435 | 4.360 |
Why?
|
| Female | 463 | 2026 | 78636 | 4.230 |
Why?
|
| Vascular Stiffness | 20 | 2025 | 486 | 4.150 |
Why?
|
| Child Development | 18 | 2026 | 483 | 4.120 |
Why?
|
| Fluorocarbons | 13 | 2026 | 119 | 4.030 |
Why?
|
| Child, Preschool | 157 | 2026 | 11835 | 3.750 |
Why?
|
| Humans | 574 | 2026 | 145140 | 3.710 |
Why?
|
| Cohort Studies | 110 | 2026 | 5988 | 3.640 |
Why?
|
| Overnutrition | 7 | 2021 | 28 | 3.350 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 14 | 2025 | 178 | 3.280 |
Why?
|
| Male | 356 | 2026 | 72664 | 3.260 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 6 | 2023 | 265 | 3.250 |
Why?
|
| Blood Glucose | 62 | 2026 | 2335 | 2.990 |
Why?
|
| Young Adult | 177 | 2026 | 14176 | 2.970 |
Why?
|
| Tobacco Smoke Pollution | 7 | 2026 | 227 | 2.970 |
Why?
|
| DNA Methylation | 24 | 2026 | 667 | 2.950 |
Why?
|
| Metformin | 26 | 2026 | 327 | 2.900 |
Why?
|
| Diabetic Angiopathies | 18 | 2025 | 264 | 2.780 |
Why?
|
| Risk Factors | 121 | 2026 | 10857 | 2.770 |
Why?
|
| Insulin | 50 | 2026 | 2510 | 2.750 |
Why?
|
| Diabetes Mellitus | 29 | 2026 | 1092 | 2.750 |
Why?
|
| Breast Feeding | 16 | 2024 | 446 | 2.720 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 7 | 2021 | 55 | 2.680 |
Why?
|
| Infant | 102 | 2026 | 10060 | 2.620 |
Why?
|
| Diabetic Ketoacidosis | 10 | 2024 | 209 | 2.620 |
Why?
|
| Prospective Studies | 65 | 2025 | 8035 | 2.600 |
Why?
|
| Fetal Blood | 20 | 2024 | 325 | 2.590 |
Why?
|
| Longitudinal Studies | 55 | 2025 | 2949 | 2.570 |
Why?
|
| Environmental Exposure | 19 | 2025 | 577 | 2.560 |
Why?
|
| Adult | 215 | 2026 | 40665 | 2.510 |
Why?
|
| Food Hypersensitivity | 4 | 2024 | 164 | 2.500 |
Why?
|
| Air Pollutants | 15 | 2025 | 405 | 2.370 |
Why?
|
| Air Pollution | 11 | 2025 | 312 | 2.250 |
Why?
|
| Biomarkers | 41 | 2026 | 4282 | 2.230 |
Why?
|
| Mothers | 23 | 2025 | 764 | 2.140 |
Why?
|
| Prevalence | 66 | 2026 | 2855 | 2.060 |
Why?
|
| Age of Onset | 27 | 2026 | 554 | 2.010 |
Why?
|
| Abdominal Fat | 5 | 2023 | 51 | 2.000 |
Why?
|
| Colorado | 41 | 2024 | 4538 | 1.970 |
Why?
|
| Weight Gain | 12 | 2023 | 561 | 1.960 |
Why?
|
| Asthma | 15 | 2025 | 1795 | 1.910 |
Why?
|
| Premature Birth | 15 | 2025 | 387 | 1.900 |
Why?
|
| Epigenesis, Genetic | 20 | 2026 | 672 | 1.890 |
Why?
|
| Plethysmography | 13 | 2022 | 104 | 1.880 |
Why?
|
| Prediabetic State | 14 | 2026 | 247 | 1.880 |
Why?
|
| Diabetes Complications | 11 | 2023 | 224 | 1.780 |
Why?
|
| Life Style | 24 | 2026 | 483 | 1.750 |
Why?
|
| Child Health | 14 | 2025 | 153 | 1.730 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 2 | 2025 | 88 | 1.730 |
Why?
|
| Blood Pressure | 20 | 2025 | 1778 | 1.700 |
Why?
|
| Hypoglycemic Agents | 31 | 2026 | 1393 | 1.670 |
Why?
|
| Adiponectin | 12 | 2025 | 241 | 1.670 |
Why?
|
| Pregnancy in Diabetics | 10 | 2018 | 123 | 1.670 |
Why?
|
| Linear Models | 24 | 2024 | 844 | 1.650 |
Why?
|
| Feeding Behavior | 13 | 2026 | 689 | 1.640 |
Why?
|
| Fatty Liver | 6 | 2026 | 253 | 1.640 |
Why?
|
| Intra-Abdominal Fat | 6 | 2023 | 101 | 1.610 |
Why?
|
| Triglycerides | 17 | 2024 | 520 | 1.570 |
Why?
|
| Pregnancy Complications | 14 | 2024 | 600 | 1.570 |
Why?
|
| United States | 109 | 2026 | 16065 | 1.570 |
Why?
|
| Albuminuria | 12 | 2026 | 189 | 1.560 |
Why?
|
| Dermatitis, Atopic | 4 | 2025 | 322 | 1.540 |
Why?
|
| Cholesterol, LDL | 10 | 2022 | 360 | 1.530 |
Why?
|
| Smoking | 8 | 2026 | 1470 | 1.500 |
Why?
|
| Adipose Tissue | 11 | 2022 | 644 | 1.480 |
Why?
|
| Food Supply | 10 | 2025 | 85 | 1.430 |
Why?
|
| Incidence | 43 | 2026 | 2915 | 1.410 |
Why?
|
| Phthalic Acids | 8 | 2025 | 41 | 1.390 |
Why?
|
| Cannabidiol | 2 | 2024 | 142 | 1.360 |
Why?
|
| Exercise | 17 | 2025 | 2191 | 1.330 |
Why?
|
| Genetic Predisposition to Disease | 22 | 2022 | 2351 | 1.320 |
Why?
|
| Dyslipidemias | 5 | 2021 | 184 | 1.300 |
Why?
|
| Overweight | 18 | 2024 | 609 | 1.300 |
Why?
|
| Health Behavior | 14 | 2025 | 787 | 1.290 |
Why?
|
| Cannabinoids | 2 | 2023 | 184 | 1.250 |
Why?
|
| Follow-Up Studies | 35 | 2026 | 5411 | 1.240 |
Why?
|
| Particulate Matter | 12 | 2025 | 325 | 1.230 |
Why?
|
| Puberty | 6 | 2024 | 136 | 1.210 |
Why?
|
| Body Weight | 13 | 2026 | 969 | 1.200 |
Why?
|
| Phenols | 7 | 2025 | 106 | 1.190 |
Why?
|
| Cognition | 8 | 2024 | 1262 | 1.130 |
Why?
|
| Indians, North American | 17 | 2025 | 598 | 1.130 |
Why?
|
| Rhinitis, Allergic | 3 | 2025 | 42 | 1.120 |
Why?
|
| Hypertension | 14 | 2025 | 1269 | 1.110 |
Why?
|
| Vitamin D | 6 | 2023 | 403 | 1.090 |
Why?
|
| Cross-Sectional Studies | 53 | 2025 | 5886 | 1.090 |
Why?
|
| Leptin | 8 | 2021 | 248 | 1.070 |
Why?
|
| Caprylates | 4 | 2025 | 19 | 1.050 |
Why?
|
| Lipids | 14 | 2020 | 706 | 1.050 |
Why?
|
| Energy Metabolism | 6 | 2021 | 933 | 1.040 |
Why?
|
| Insulin-Secreting Cells | 8 | 2017 | 392 | 1.040 |
Why?
|
| Carbon Isotopes | 2 | 2025 | 143 | 1.040 |
Why?
|
| Autism Spectrum Disorder | 6 | 2025 | 420 | 1.010 |
Why?
|
| Hyperinsulinism | 2 | 2021 | 114 | 1.000 |
Why?
|
| Age Factors | 32 | 2024 | 3338 | 0.990 |
Why?
|
| Pregnancy Outcome | 10 | 2026 | 500 | 0.990 |
Why?
|
| Diabetic Neuropathies | 8 | 2025 | 100 | 0.940 |
Why?
|
| Adolescent Behavior | 6 | 2024 | 494 | 0.940 |
Why?
|
| Energy Intake | 7 | 2025 | 507 | 0.940 |
Why?
|
| Cannabis | 2 | 2023 | 509 | 0.900 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2025 | 2136 | 0.880 |
Why?
|
| Heart Rate | 7 | 2022 | 855 | 0.870 |
Why?
|
| Inflammation | 10 | 2026 | 2876 | 0.870 |
Why?
|
| Polymorphism, Genetic | 7 | 2025 | 614 | 0.860 |
Why?
|
| Waist Circumference | 11 | 2026 | 143 | 0.850 |
Why?
|
| Anthropometry | 9 | 2022 | 205 | 0.850 |
Why?
|
| Autoantibodies | 12 | 2026 | 1508 | 0.840 |
Why?
|
| Cotinine | 4 | 2026 | 76 | 0.840 |
Why?
|
| Gestational Age | 17 | 2026 | 987 | 0.840 |
Why?
|
| Islets of Langerhans | 7 | 2021 | 846 | 0.830 |
Why?
|
| Pulse Wave Analysis | 14 | 2025 | 267 | 0.830 |
Why?
|
| Sex Factors | 19 | 2025 | 2099 | 0.820 |
Why?
|
| Liver | 4 | 2026 | 1893 | 0.820 |
Why?
|
| Infant, Small for Gestational Age | 5 | 2025 | 118 | 0.800 |
Why?
|
| Calcinosis | 7 | 2023 | 234 | 0.800 |
Why?
|
| Oxytocin | 1 | 2024 | 51 | 0.800 |
Why?
|
| Hypertension, Pregnancy-Induced | 5 | 2025 | 69 | 0.790 |
Why?
|
| Vehicle Emissions | 3 | 2021 | 57 | 0.790 |
Why?
|
| Postal Service | 2 | 2016 | 27 | 0.790 |
Why?
|
| Body Height | 8 | 2026 | 201 | 0.780 |
Why?
|
| Electronic Health Records | 9 | 2026 | 1188 | 0.770 |
Why?
|
| Subcutaneous Fat | 4 | 2019 | 79 | 0.760 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2025 | 186 | 0.760 |
Why?
|
| Immunoglobulin E | 1 | 2024 | 315 | 0.740 |
Why?
|
| Child Behavior | 5 | 2025 | 236 | 0.730 |
Why?
|
| Hyperglycemia | 8 | 2021 | 379 | 0.720 |
Why?
|
| Health Status | 5 | 2024 | 832 | 0.720 |
Why?
|
| Vitamins | 5 | 2023 | 182 | 0.700 |
Why?
|
| HLA Antigens | 4 | 2014 | 238 | 0.700 |
Why?
|
| Healthy Lifestyle | 2 | 2026 | 37 | 0.700 |
Why?
|
| Parabens | 4 | 2025 | 11 | 0.700 |
Why?
|
| Dronabinol | 1 | 2024 | 249 | 0.700 |
Why?
|
| Dietary Carbohydrates | 3 | 2019 | 147 | 0.700 |
Why?
|
| Insulins | 1 | 2022 | 38 | 0.690 |
Why?
|
| Diabetic Nephropathies | 8 | 2026 | 319 | 0.680 |
Why?
|
| Eczema | 1 | 2022 | 66 | 0.680 |
Why?
|
| Cardiovascular System | 1 | 2023 | 138 | 0.680 |
Why?
|
| Hypersensitivity | 1 | 2024 | 254 | 0.680 |
Why?
|
| Registries | 13 | 2026 | 2401 | 0.680 |
Why?
|
| Socioeconomic Factors | 20 | 2026 | 1321 | 0.680 |
Why?
|
| Mental Health | 4 | 2025 | 791 | 0.670 |
Why?
|
| Lipoproteins, HDL | 3 | 2017 | 100 | 0.670 |
Why?
|
| Glutamate Decarboxylase | 5 | 2021 | 165 | 0.660 |
Why?
|
| Vaccines | 2 | 2023 | 388 | 0.660 |
Why?
|
| Diet Surveys | 6 | 2021 | 90 | 0.660 |
Why?
|
| Hallucinogens | 1 | 2023 | 111 | 0.660 |
Why?
|
| Metabolic Diseases | 2 | 2021 | 114 | 0.650 |
Why?
|
| Motor Activity | 6 | 2015 | 718 | 0.650 |
Why?
|
| Residence Characteristics | 10 | 2025 | 373 | 0.640 |
Why?
|
| Dietary Supplements | 6 | 2024 | 582 | 0.640 |
Why?
|
| Stress, Psychological | 7 | 2026 | 1145 | 0.630 |
Why?
|
| Case-Control Studies | 24 | 2025 | 3616 | 0.630 |
Why?
|
| Diabetic Retinopathy | 6 | 2025 | 209 | 0.630 |
Why?
|
| Comorbidity | 7 | 2025 | 1657 | 0.630 |
Why?
|
| Alkanesulfonic Acids | 5 | 2025 | 34 | 0.630 |
Why?
|
| Chemokines | 1 | 2021 | 217 | 0.620 |
Why?
|
| Mitochondria, Muscle | 2 | 2021 | 120 | 0.620 |
Why?
|
| Logistic Models | 18 | 2023 | 2133 | 0.610 |
Why?
|
| Lipid Metabolism | 8 | 2024 | 529 | 0.610 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2024 | 427 | 0.610 |
Why?
|
| National Institute of Child Health and Human Development (U.S.) | 2 | 2016 | 8 | 0.600 |
Why?
|
| C-Peptide | 8 | 2024 | 190 | 0.600 |
Why?
|
| Prenatal Care | 2 | 2023 | 309 | 0.590 |
Why?
|
| Genotype | 9 | 2026 | 1844 | 0.590 |
Why?
|
| Vitamin D Deficiency | 2 | 2019 | 190 | 0.590 |
Why?
|
| Social Class | 6 | 2025 | 264 | 0.580 |
Why?
|
| Metabolome | 3 | 2025 | 387 | 0.580 |
Why?
|
| Glucose Tolerance Test | 9 | 2025 | 360 | 0.580 |
Why?
|
| Puberty, Precocious | 1 | 2018 | 12 | 0.580 |
Why?
|
| Glucose Intolerance | 10 | 2017 | 142 | 0.570 |
Why?
|
| Community-Institutional Relations | 2 | 2016 | 100 | 0.570 |
Why?
|
| Coronary Artery Disease | 8 | 2023 | 747 | 0.570 |
Why?
|
| Gastrointestinal Microbiome | 5 | 2019 | 766 | 0.560 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2020 | 115 | 0.560 |
Why?
|
| Transition to Adult Care | 2 | 2018 | 101 | 0.560 |
Why?
|
| Child Welfare | 2 | 2012 | 233 | 0.560 |
Why?
|
| Maternal Health | 3 | 2019 | 50 | 0.560 |
Why?
|
| Adenosine Diphosphate | 2 | 2021 | 83 | 0.550 |
Why?
|
| Genome-Wide Association Study | 12 | 2025 | 1376 | 0.530 |
Why?
|
| Health Promotion | 5 | 2023 | 774 | 0.520 |
Why?
|
| Niacin | 1 | 2017 | 16 | 0.520 |
Why?
|
| Body Fluid Compartments | 1 | 2017 | 6 | 0.520 |
Why?
|
| Patient Selection | 3 | 2016 | 733 | 0.520 |
Why?
|
| Multivariate Analysis | 14 | 2017 | 1546 | 0.510 |
Why?
|
| Fasting | 11 | 2023 | 276 | 0.510 |
Why?
|
| Disease Progression | 15 | 2021 | 2857 | 0.510 |
Why?
|
| Health Surveys | 4 | 2021 | 517 | 0.510 |
Why?
|
| Placenta | 5 | 2026 | 784 | 0.500 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 3 | 2014 | 54 | 0.490 |
Why?
|
| Regression Analysis | 9 | 2019 | 998 | 0.480 |
Why?
|
| Self Report | 6 | 2023 | 867 | 0.480 |
Why?
|
| Flame Retardants | 2 | 2026 | 10 | 0.480 |
Why?
|
| Metabolomics | 6 | 2026 | 730 | 0.480 |
Why?
|
| Organophosphates | 3 | 2026 | 179 | 0.480 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2016 | 10 | 0.480 |
Why?
|
| Cholesterol, HDL | 5 | 2021 | 201 | 0.480 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2019 | 226 | 0.470 |
Why?
|
| Autonomic Nervous System | 2 | 2013 | 82 | 0.470 |
Why?
|
| Sex Characteristics | 2 | 2020 | 775 | 0.470 |
Why?
|
| Risk Reduction Behavior | 4 | 2025 | 217 | 0.470 |
Why?
|
| Public Health | 3 | 2025 | 571 | 0.460 |
Why?
|
| Cytokines | 2 | 2021 | 2048 | 0.460 |
Why?
|
| Diet, High-Fat | 1 | 2017 | 266 | 0.460 |
Why?
|
| Child of Impaired Parents | 2 | 2015 | 38 | 0.460 |
Why?
|
| Micronutrients | 3 | 2023 | 102 | 0.450 |
Why?
|
| Epidemiologic Studies | 2 | 2018 | 68 | 0.450 |
Why?
|
| Fetal Diseases | 1 | 2017 | 194 | 0.450 |
Why?
|
| Glucose | 9 | 2023 | 1048 | 0.450 |
Why?
|
| Predictive Value of Tests | 13 | 2021 | 2115 | 0.450 |
Why?
|
| Risk Assessment | 12 | 2024 | 3740 | 0.450 |
Why?
|
| Beverages | 3 | 2026 | 68 | 0.440 |
Why?
|
| Dietary Fats | 3 | 2016 | 308 | 0.440 |
Why?
|
| Dietary Proteins | 1 | 2016 | 135 | 0.440 |
Why?
|
| Patient Compliance | 4 | 2016 | 587 | 0.430 |
Why?
|
| Apolipoproteins B | 5 | 2012 | 47 | 0.430 |
Why?
|
| Folic Acid | 6 | 2023 | 198 | 0.430 |
Why?
|
| Television | 3 | 2015 | 72 | 0.430 |
Why?
|
| Algorithms | 7 | 2024 | 1845 | 0.430 |
Why?
|
| Smoking Cessation | 1 | 2018 | 437 | 0.420 |
Why?
|
| Fatty Acids, Omega-3 | 4 | 2024 | 142 | 0.420 |
Why?
|
| Testosterone | 4 | 2024 | 415 | 0.420 |
Why?
|
| Metabolic Syndrome | 5 | 2021 | 360 | 0.420 |
Why?
|
| Creatinine | 4 | 2016 | 513 | 0.420 |
Why?
|
| Surveys and Questionnaires | 19 | 2019 | 6055 | 0.420 |
Why?
|
| Odds Ratio | 10 | 2023 | 1082 | 0.420 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 2 | 2011 | 26 | 0.410 |
Why?
|
| Mental Recall | 3 | 2021 | 217 | 0.410 |
Why?
|
| Physical Fitness | 2 | 2012 | 207 | 0.410 |
Why?
|
| Vaccination | 1 | 2022 | 1423 | 0.400 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2014 | 34 | 0.400 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2015 | 170 | 0.400 |
Why?
|
| Endocrine Disruptors | 3 | 2025 | 40 | 0.400 |
Why?
|
| Lipase | 2 | 2026 | 75 | 0.390 |
Why?
|
| Homeostasis | 4 | 2021 | 639 | 0.390 |
Why?
|
| Proportional Hazards Models | 12 | 2026 | 1325 | 0.390 |
Why?
|
| Muscle Cells | 2 | 2017 | 41 | 0.390 |
Why?
|
| Vitamin A | 2 | 2023 | 60 | 0.390 |
Why?
|
| Retrospective Studies | 20 | 2026 | 17247 | 0.380 |
Why?
|
| Infant, Low Birth Weight | 4 | 2024 | 156 | 0.380 |
Why?
|
| Risk | 8 | 2024 | 916 | 0.380 |
Why?
|
| Adolescent Development | 1 | 2013 | 72 | 0.380 |
Why?
|
| Ohio | 6 | 2015 | 146 | 0.380 |
Why?
|
| Time Factors | 14 | 2024 | 7107 | 0.380 |
Why?
|
| Prognosis | 7 | 2026 | 4310 | 0.370 |
Why?
|
| Vegetables | 5 | 2023 | 161 | 0.370 |
Why?
|
| Nutrition Policy | 4 | 2023 | 57 | 0.370 |
Why?
|
| Middle Aged | 47 | 2026 | 36126 | 0.360 |
Why?
|
| Carotid Arteries | 1 | 2013 | 208 | 0.360 |
Why?
|
| Fatty Acids, Nonesterified | 4 | 2022 | 154 | 0.360 |
Why?
|
| Femoral Artery | 1 | 2013 | 190 | 0.360 |
Why?
|
| Data Collection | 4 | 2022 | 639 | 0.360 |
Why?
|
| Depression | 7 | 2025 | 1537 | 0.360 |
Why?
|
| Calcium | 8 | 2023 | 1189 | 0.360 |
Why?
|
| Pandemics | 8 | 2023 | 1703 | 0.350 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2026 | 3892 | 0.350 |
Why?
|
| Poverty | 6 | 2025 | 525 | 0.340 |
Why?
|
| Arteries | 2 | 2010 | 261 | 0.340 |
Why?
|
| Autistic Disorder | 3 | 2024 | 218 | 0.340 |
Why?
|
| Down-Regulation | 1 | 2013 | 618 | 0.330 |
Why?
|
| Maternal Age | 4 | 2021 | 127 | 0.330 |
Why?
|
| Nutrition Assessment | 2 | 2021 | 90 | 0.330 |
Why?
|
| Sugars | 2 | 2023 | 40 | 0.330 |
Why?
|
| Pre-Eclampsia | 2 | 2024 | 206 | 0.330 |
Why?
|
| Hydrocortisone | 2 | 2025 | 298 | 0.330 |
Why?
|
| Fetal Development | 5 | 2026 | 298 | 0.330 |
Why?
|
| Autoimmunity | 6 | 2021 | 932 | 0.330 |
Why?
|
| Self Concept | 1 | 2012 | 253 | 0.320 |
Why?
|
| Respiratory Sounds | 2 | 2021 | 103 | 0.320 |
Why?
|
| Geographic Information Systems | 2 | 2012 | 45 | 0.320 |
Why?
|
| Pesticides | 2 | 2022 | 59 | 0.320 |
Why?
|
| DNA Helicases | 1 | 2012 | 136 | 0.320 |
Why?
|
| Educational Status | 4 | 2025 | 465 | 0.320 |
Why?
|
| Population Surveillance | 6 | 2016 | 484 | 0.310 |
Why?
|
| Bayes Theorem | 5 | 2023 | 419 | 0.310 |
Why?
|
| Membrane Proteins | 4 | 2026 | 1163 | 0.310 |
Why?
|
| Fatty Acids | 4 | 2024 | 457 | 0.300 |
Why?
|
| Arsenic | 2 | 2023 | 65 | 0.300 |
Why?
|
| Cesarean Section | 1 | 2012 | 229 | 0.300 |
Why?
|
| Eating | 6 | 2023 | 387 | 0.300 |
Why?
|
| Gene-Environment Interaction | 2 | 2021 | 178 | 0.300 |
Why?
|
| Cost of Illness | 2 | 2026 | 324 | 0.300 |
Why?
|
| Fetal Growth Retardation | 2 | 2023 | 592 | 0.290 |
Why?
|
| Minority Groups | 6 | 2023 | 284 | 0.290 |
Why?
|
| Diet, Mediterranean | 2 | 2022 | 27 | 0.290 |
Why?
|
| C-Reactive Protein | 6 | 2026 | 422 | 0.290 |
Why?
|
| Alleles | 6 | 2021 | 888 | 0.290 |
Why?
|
| Lipoproteins | 2 | 2016 | 166 | 0.290 |
Why?
|
| Phenotype | 12 | 2026 | 3138 | 0.290 |
Why?
|
| Adipogenesis | 3 | 2023 | 56 | 0.280 |
Why?
|
| Hypoglycemia | 3 | 2024 | 479 | 0.280 |
Why?
|
| Treatment Outcome | 14 | 2026 | 11741 | 0.270 |
Why?
|
| Denmark | 3 | 2026 | 50 | 0.270 |
Why?
|
| CpG Islands | 6 | 2024 | 161 | 0.270 |
Why?
|
| Hunger | 2 | 2019 | 56 | 0.260 |
Why?
|
| Analysis of Variance | 5 | 2018 | 1300 | 0.260 |
Why?
|
| Soot | 2 | 2024 | 23 | 0.260 |
Why?
|
| South Carolina | 4 | 2012 | 47 | 0.260 |
Why?
|
| Precision Medicine | 3 | 2023 | 459 | 0.260 |
Why?
|
| Autoimmune Diseases | 3 | 2026 | 468 | 0.260 |
Why?
|
| American Heart Association | 2 | 2023 | 357 | 0.260 |
Why?
|
| Executive Function | 2 | 2025 | 469 | 0.250 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2026 | 454 | 0.250 |
Why?
|
| Phenol | 2 | 2023 | 15 | 0.250 |
Why?
|
| Weight Loss | 5 | 2021 | 845 | 0.240 |
Why?
|
| Health Status Disparities | 3 | 2026 | 320 | 0.240 |
Why?
|
| Body Size | 2 | 2020 | 88 | 0.240 |
Why?
|
| Carotid Intima-Media Thickness | 3 | 2017 | 75 | 0.240 |
Why?
|
| Plasticizers | 1 | 2026 | 18 | 0.240 |
Why?
|
| Chronic Disease | 6 | 2026 | 1806 | 0.240 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2019 | 104 | 0.240 |
Why?
|
| Diet Records | 4 | 2021 | 89 | 0.240 |
Why?
|
| Fruit and Vegetable Juices | 1 | 2026 | 21 | 0.240 |
Why?
|
| Benzhydryl Compounds | 2 | 2024 | 80 | 0.240 |
Why?
|
| Mental Disorders | 2 | 2026 | 1154 | 0.230 |
Why?
|
| Causality | 2 | 2020 | 126 | 0.230 |
Why?
|
| Phospholipases A2, Calcium-Independent | 2 | 2026 | 18 | 0.230 |
Why?
|
| Microvessels | 2 | 2019 | 97 | 0.230 |
Why?
|
| Multimorbidity | 1 | 2026 | 64 | 0.230 |
Why?
|
| Weight Reduction Programs | 2 | 2017 | 138 | 0.230 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 2 | 2017 | 15 | 0.230 |
Why?
|
| Nitrogen Dioxide | 1 | 2025 | 45 | 0.230 |
Why?
|
| Blood Glucose Self-Monitoring | 6 | 2023 | 699 | 0.230 |
Why?
|
| Epigenomics | 3 | 2025 | 112 | 0.230 |
Why?
|
| Mass Screening | 5 | 2020 | 1354 | 0.230 |
Why?
|
| Coronary Disease | 3 | 2007 | 381 | 0.230 |
Why?
|
| Dietary Sugars | 1 | 2025 | 21 | 0.220 |
Why?
|
| Acyltransferases | 2 | 2026 | 78 | 0.220 |
Why?
|
| Internet | 1 | 2010 | 689 | 0.220 |
Why?
|
| Organophosphorus Compounds | 1 | 2026 | 84 | 0.220 |
Why?
|
| Pregnancy Trimesters | 3 | 2025 | 20 | 0.220 |
Why?
|
| Protective Factors | 3 | 2021 | 99 | 0.220 |
Why?
|
| Wildfires | 1 | 2025 | 41 | 0.220 |
Why?
|
| Language Development | 1 | 2025 | 59 | 0.220 |
Why?
|
| Retinal Diseases | 2 | 2023 | 101 | 0.210 |
Why?
|
| Fetal Macrosomia | 2 | 2018 | 63 | 0.210 |
Why?
|
| Health | 2 | 2015 | 82 | 0.210 |
Why?
|
| Health Services Accessibility | 4 | 2020 | 1099 | 0.210 |
Why?
|
| Menarche | 2 | 2018 | 52 | 0.210 |
Why?
|
| Smoke | 1 | 2025 | 148 | 0.210 |
Why?
|
| Psychopathology | 1 | 2024 | 54 | 0.210 |
Why?
|
| Insurance, Health | 3 | 2023 | 310 | 0.210 |
Why?
|
| Diethylhexyl Phthalate | 1 | 2024 | 13 | 0.200 |
Why?
|
| Social Segregation | 1 | 2023 | 3 | 0.200 |
Why?
|
| Benzophenones | 1 | 2023 | 15 | 0.200 |
Why?
|
| Chlorophenols | 1 | 2023 | 12 | 0.200 |
Why?
|
| Parturition | 2 | 2022 | 68 | 0.200 |
Why?
|
| Polyneuropathies | 1 | 2024 | 57 | 0.200 |
Why?
|
| AMP-Activated Protein Kinases | 3 | 2024 | 192 | 0.200 |
Why?
|
| Rubella | 1 | 2023 | 23 | 0.200 |
Why?
|
| Pregnancy Trimester, Second | 3 | 2021 | 83 | 0.200 |
Why?
|
| Mumps | 1 | 2023 | 21 | 0.200 |
Why?
|
| Lead | 1 | 2024 | 71 | 0.200 |
Why?
|
| Racism | 1 | 2026 | 146 | 0.200 |
Why?
|
| Aged | 17 | 2026 | 26096 | 0.200 |
Why?
|
| HLA-DQ beta-Chains | 3 | 2019 | 58 | 0.200 |
Why?
|
| Measles | 1 | 2023 | 46 | 0.190 |
Why?
|
| Circadian Clocks | 1 | 2023 | 59 | 0.190 |
Why?
|
| Vulnerable Populations | 1 | 2024 | 175 | 0.190 |
Why?
|
| Chickenpox | 1 | 2023 | 82 | 0.190 |
Why?
|
| Preconception Care | 1 | 2023 | 50 | 0.190 |
Why?
|
| Appetite | 1 | 2023 | 79 | 0.190 |
Why?
|
| Psychological Tests | 1 | 2023 | 130 | 0.190 |
Why?
|
| HLA-DRB1 Chains | 3 | 2019 | 110 | 0.190 |
Why?
|
| Parents | 6 | 2022 | 1401 | 0.190 |
Why?
|
| India | 2 | 2020 | 213 | 0.190 |
Why?
|
| Food Assistance | 1 | 2023 | 29 | 0.190 |
Why?
|
| Cholesterol | 4 | 2023 | 406 | 0.190 |
Why?
|
| Population Health | 1 | 2023 | 44 | 0.180 |
Why?
|
| Behavior Therapy | 1 | 2025 | 294 | 0.180 |
Why?
|
| Infant, Premature | 3 | 2025 | 619 | 0.180 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2022 | 11 | 0.180 |
Why?
|
| Child Nutritional Physiological Phenomena | 2 | 2013 | 106 | 0.180 |
Why?
|
| Reference Values | 5 | 2012 | 798 | 0.180 |
Why?
|
| Nutritional Status | 4 | 2018 | 353 | 0.180 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2022 | 21 | 0.180 |
Why?
|
| Vascular Calcification | 1 | 2023 | 110 | 0.180 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2022 | 15 | 0.180 |
Why?
|
| Satiation | 2 | 2023 | 26 | 0.180 |
Why?
|
| Drinking Water | 1 | 2023 | 89 | 0.180 |
Why?
|
| Societies, Medical | 4 | 2022 | 898 | 0.180 |
Why?
|
| Starch | 1 | 2022 | 22 | 0.180 |
Why?
|
| Pregnancy Proteins | 1 | 2022 | 35 | 0.180 |
Why?
|
| Umbilical Cord | 3 | 2017 | 92 | 0.180 |
Why?
|
| Health Care Costs | 1 | 2025 | 425 | 0.170 |
Why?
|
| Kidney Diseases | 2 | 2023 | 424 | 0.170 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2018 | 507 | 0.170 |
Why?
|
| Ozone | 1 | 2022 | 115 | 0.170 |
Why?
|
| Cortisone | 1 | 2021 | 16 | 0.170 |
Why?
|
| Breast Neoplasms | 2 | 2011 | 2380 | 0.170 |
Why?
|
| Age Distribution | 3 | 2019 | 402 | 0.170 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2021 | 27 | 0.170 |
Why?
|
| Arizona | 6 | 2000 | 80 | 0.170 |
Why?
|
| Food | 1 | 2022 | 150 | 0.170 |
Why?
|
| Endotoxins | 1 | 2022 | 217 | 0.170 |
Why?
|
| Immunization Schedule | 1 | 2022 | 186 | 0.170 |
Why?
|
| Signal Transduction | 3 | 2026 | 5208 | 0.170 |
Why?
|
| Allergens | 1 | 2024 | 386 | 0.170 |
Why?
|
| Autonomic Nervous System Diseases | 2 | 2019 | 37 | 0.170 |
Why?
|
| Insurance Coverage | 2 | 2025 | 244 | 0.170 |
Why?
|
| Allostasis | 1 | 2021 | 17 | 0.170 |
Why?
|
| Health Services, Indigenous | 1 | 2021 | 36 | 0.170 |
Why?
|
| Esters | 3 | 2026 | 71 | 0.170 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2021 | 10 | 0.170 |
Why?
|
| Pregnanolone | 1 | 2021 | 34 | 0.170 |
Why?
|
| Patient Education as Topic | 4 | 2018 | 775 | 0.170 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2021 | 17 | 0.170 |
Why?
|
| Quality of Life | 8 | 2024 | 3194 | 0.170 |
Why?
|
| Calcium, Dietary | 4 | 2023 | 52 | 0.170 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2021 | 39 | 0.170 |
Why?
|
| Depression, Postpartum | 1 | 2022 | 116 | 0.160 |
Why?
|
| Latent Autoimmune Diabetes in Adults | 1 | 2020 | 3 | 0.160 |
Why?
|
| Glycation End Products, Advanced | 1 | 2021 | 81 | 0.160 |
Why?
|
| Nutrition Surveys | 5 | 2024 | 279 | 0.160 |
Why?
|
| Motivational Interviewing | 2 | 2025 | 121 | 0.160 |
Why?
|
| Immunization | 1 | 2022 | 375 | 0.160 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2021 | 123 | 0.160 |
Why?
|
| Cognitive Dysfunction | 2 | 2023 | 465 | 0.160 |
Why?
|
| Macular Degeneration | 1 | 2023 | 191 | 0.160 |
Why?
|
| Epidemiological Monitoring | 1 | 2021 | 69 | 0.160 |
Why?
|
| Slovenia | 1 | 2020 | 3 | 0.160 |
Why?
|
| Phospholipids | 2 | 2019 | 214 | 0.160 |
Why?
|
| Gene Expression | 3 | 2023 | 1474 | 0.160 |
Why?
|
| Immunoglobulin G | 2 | 2022 | 887 | 0.160 |
Why?
|
| Cluster Analysis | 4 | 2026 | 500 | 0.160 |
Why?
|
| Genetic Markers | 1 | 2021 | 333 | 0.160 |
Why?
|
| Muscle, Skeletal | 3 | 2021 | 1789 | 0.160 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 133 | 0.160 |
Why?
|
| Klinefelter Syndrome | 1 | 2021 | 69 | 0.160 |
Why?
|
| Chromosome Mapping | 1 | 2021 | 504 | 0.160 |
Why?
|
| Brachial Artery | 2 | 2013 | 208 | 0.160 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2018 | 118 | 0.160 |
Why?
|
| Fibrinogen | 4 | 2019 | 180 | 0.160 |
Why?
|
| Depressive Disorder | 1 | 2023 | 372 | 0.150 |
Why?
|
| Progesterone | 1 | 2021 | 214 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2023 | 286 | 0.150 |
Why?
|
| Germany | 1 | 2020 | 137 | 0.150 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2021 | 264 | 0.150 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 2 | 2012 | 46 | 0.150 |
Why?
|
| Thioctic Acid | 1 | 1999 | 12 | 0.150 |
Why?
|
| Waist-Height Ratio | 1 | 2019 | 8 | 0.150 |
Why?
|
| Dehydroepiandrosterone | 1 | 2019 | 49 | 0.150 |
Why?
|
| Interleukin-6 | 4 | 2026 | 775 | 0.150 |
Why?
|
| Principal Component Analysis | 1 | 2019 | 191 | 0.150 |
Why?
|
| Demography | 1 | 2020 | 282 | 0.140 |
Why?
|
| Ventricular Remodeling | 1 | 2021 | 277 | 0.140 |
Why?
|
| Research Design | 2 | 2023 | 1132 | 0.140 |
Why?
|
| HLA-D Antigens | 1 | 2019 | 30 | 0.140 |
Why?
|
| Sexual and Gender Minorities | 1 | 2023 | 259 | 0.140 |
Why?
|
| Diagnostic Techniques, Endocrine | 1 | 2018 | 14 | 0.140 |
Why?
|
| Healthcare Disparities | 3 | 2023 | 731 | 0.140 |
Why?
|
| Sexual Maturation | 1 | 2018 | 48 | 0.140 |
Why?
|
| Lipopolysaccharides | 1 | 2022 | 858 | 0.140 |
Why?
|
| Genetic Variation | 2 | 2021 | 967 | 0.140 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2021 | 627 | 0.140 |
Why?
|
| Luteinizing Hormone | 1 | 2019 | 206 | 0.140 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2021 | 317 | 0.140 |
Why?
|
| Guideline Adherence | 2 | 2014 | 586 | 0.140 |
Why?
|
| Apolipoproteins A | 2 | 1995 | 19 | 0.140 |
Why?
|
| Sleep Wake Disorders | 1 | 2022 | 310 | 0.140 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 3410 | 0.140 |
Why?
|
| Anxiety | 1 | 2025 | 1117 | 0.140 |
Why?
|
| Echocardiography | 1 | 2021 | 647 | 0.140 |
Why?
|
| Self Efficacy | 2 | 2018 | 410 | 0.140 |
Why?
|
| Glomerular Filtration Rate | 2 | 2020 | 765 | 0.140 |
Why?
|
| Exome | 1 | 2019 | 227 | 0.130 |
Why?
|
| Epidemiologic Research Design | 1 | 2018 | 29 | 0.130 |
Why?
|
| Mutation | 3 | 2022 | 4071 | 0.130 |
Why?
|
| PPAR gamma | 2 | 2016 | 178 | 0.130 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2018 | 45 | 0.130 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2021 | 393 | 0.130 |
Why?
|
| Family | 2 | 2023 | 682 | 0.130 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 539 | 0.130 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2023 | 411 | 0.130 |
Why?
|
| Multicenter Studies as Topic | 2 | 2016 | 410 | 0.130 |
Why?
|
| Family Characteristics | 3 | 2023 | 195 | 0.130 |
Why?
|
| Glucokinase | 2 | 2017 | 15 | 0.130 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 2 | 2017 | 21 | 0.130 |
Why?
|
| Trans Fatty Acids | 1 | 2017 | 5 | 0.130 |
Why?
|
| Pediatrics | 3 | 2018 | 1121 | 0.130 |
Why?
|
| Skinfold Thickness | 2 | 2020 | 43 | 0.130 |
Why?
|
| Phosphorus Isotopes | 1 | 2017 | 8 | 0.130 |
Why?
|
| Endocrinology | 1 | 2018 | 77 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 497 | 0.130 |
Why?
|
| Rheumatoid Factor | 1 | 2018 | 178 | 0.130 |
Why?
|
| Cystatin C | 1 | 2017 | 66 | 0.130 |
Why?
|
| Granuloma | 1 | 2017 | 97 | 0.130 |
Why?
|
| Coronary Vessels | 4 | 2023 | 246 | 0.130 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2017 | 55 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2023 | 881 | 0.130 |
Why?
|
| Brain | 2 | 2020 | 2934 | 0.130 |
Why?
|
| History, 21st Century | 1 | 2018 | 220 | 0.130 |
Why?
|
| Awards and Prizes | 1 | 2018 | 71 | 0.130 |
Why?
|
| Fear | 1 | 2020 | 367 | 0.120 |
Why?
|
| Anti-Citrullinated Protein Antibodies | 1 | 2018 | 127 | 0.120 |
Why?
|
| Leisure Activities | 1 | 2016 | 30 | 0.120 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 558 | 0.120 |
Why?
|
| Genome, Human | 1 | 2019 | 419 | 0.120 |
Why?
|
| Feeding and Eating Disorders | 1 | 2019 | 162 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2018 | 327 | 0.120 |
Why?
|
| Reward | 1 | 2019 | 248 | 0.120 |
Why?
|
| Combined Modality Therapy | 3 | 2015 | 1264 | 0.120 |
Why?
|
| Pilot Projects | 6 | 2023 | 1889 | 0.120 |
Why?
|
| Needs Assessment | 3 | 2016 | 401 | 0.120 |
Why?
|
| Animals | 11 | 2024 | 37952 | 0.120 |
Why?
|
| Gastrointestinal Tract | 1 | 2019 | 204 | 0.120 |
Why?
|
| Dietary Fiber | 2 | 2014 | 59 | 0.120 |
Why?
|
| Postpartum Period | 1 | 2019 | 372 | 0.120 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2017 | 143 | 0.120 |
Why?
|
| Carbon | 3 | 2023 | 176 | 0.120 |
Why?
|
| Blood Pressure Determination | 1 | 2017 | 145 | 0.120 |
Why?
|
| Evidence-Based Medicine | 2 | 2023 | 739 | 0.120 |
Why?
|
| Mexico | 2 | 2011 | 232 | 0.120 |
Why?
|
| Oxidative Phosphorylation | 1 | 2017 | 209 | 0.120 |
Why?
|
| Genomics | 1 | 2021 | 819 | 0.120 |
Why?
|
| Language | 1 | 2019 | 322 | 0.120 |
Why?
|
| Niacinamide | 1 | 2016 | 87 | 0.120 |
Why?
|
| Vitamin B 12 | 1 | 2016 | 135 | 0.120 |
Why?
|
| Bacteria | 2 | 2018 | 765 | 0.120 |
Why?
|
| Choristoma | 1 | 2015 | 20 | 0.120 |
Why?
|
| Exercise Therapy | 2 | 2017 | 475 | 0.120 |
Why?
|
| Genetic Testing | 1 | 2019 | 480 | 0.120 |
Why?
|
| Antioxidants | 1 | 1999 | 550 | 0.110 |
Why?
|
| Nutrition Therapy | 2 | 2013 | 37 | 0.110 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2015 | 83 | 0.110 |
Why?
|
| Haplotypes | 2 | 2019 | 498 | 0.110 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2015 | 16 | 0.110 |
Why?
|
| Apolipoprotein A-I | 1 | 1995 | 39 | 0.110 |
Why?
|
| Polyendocrinopathies, Autoimmune | 1 | 2015 | 18 | 0.110 |
Why?
|
| Sulfonylurea Receptors | 2 | 2012 | 4 | 0.110 |
Why?
|
| Microbiota | 2 | 2019 | 729 | 0.110 |
Why?
|
| Feces | 1 | 2018 | 494 | 0.110 |
Why?
|
| Cognition Disorders | 1 | 2019 | 539 | 0.110 |
Why?
|
| Emigrants and Immigrants | 3 | 2012 | 157 | 0.110 |
Why?
|
| Phylogeny | 1 | 2018 | 917 | 0.110 |
Why?
|
| Personal Satisfaction | 1 | 2016 | 218 | 0.110 |
Why?
|
| Resilience, Psychological | 1 | 2016 | 149 | 0.100 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 1210 | 0.100 |
Why?
|
| Computers | 1 | 2014 | 66 | 0.100 |
Why?
|
| Carbonated Beverages | 2 | 2011 | 16 | 0.100 |
Why?
|
| Seafood | 2 | 2024 | 25 | 0.100 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 1134 | 0.100 |
Why?
|
| Muscle Strength | 1 | 2017 | 332 | 0.100 |
Why?
|
| Family Health | 1 | 2015 | 190 | 0.100 |
Why?
|
| Vasculitis | 1 | 2014 | 69 | 0.100 |
Why?
|
| Nutritional Requirements | 2 | 2021 | 78 | 0.100 |
Why?
|
| Proteinuria | 1 | 1994 | 104 | 0.100 |
Why?
|
| Romania | 5 | 2001 | 12 | 0.100 |
Why?
|
| Fishes | 2 | 2024 | 109 | 0.100 |
Why?
|
| Global Health | 3 | 2025 | 403 | 0.100 |
Why?
|
| Muscle Development | 3 | 2021 | 112 | 0.100 |
Why?
|
| beta Catenin | 1 | 2015 | 254 | 0.100 |
Why?
|
| SEER Program | 2 | 2011 | 229 | 0.100 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2015 | 248 | 0.100 |
Why?
|
| Managed Care Programs | 1 | 2013 | 140 | 0.090 |
Why?
|
| Cation Transport Proteins | 1 | 2014 | 118 | 0.090 |
Why?
|
| Rural Population | 1 | 2018 | 657 | 0.090 |
Why?
|
| Transients and Migrants | 1 | 2012 | 27 | 0.090 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2017 | 909 | 0.090 |
Why?
|
| DNA | 1 | 2019 | 1433 | 0.090 |
Why?
|
| Body Constitution | 1 | 2012 | 51 | 0.090 |
Why?
|
| Guidelines as Topic | 1 | 2014 | 266 | 0.090 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2014 | 159 | 0.090 |
Why?
|
| Insulin, Regular, Human | 2 | 2022 | 47 | 0.090 |
Why?
|
| Statistics, Nonparametric | 4 | 2017 | 427 | 0.090 |
Why?
|
| HLA-DP beta-Chains | 1 | 2012 | 88 | 0.090 |
Why?
|
| Intracellular Space | 1 | 2012 | 64 | 0.090 |
Why?
|
| Mammary Glands, Human | 1 | 2012 | 68 | 0.090 |
Why?
|
| Europe | 2 | 2011 | 416 | 0.090 |
Why?
|
| Preventive Health Services | 1 | 2013 | 153 | 0.090 |
Why?
|
| DNA-Binding Proteins | 1 | 2019 | 1479 | 0.090 |
Why?
|
| Sleep | 3 | 2024 | 887 | 0.090 |
Why?
|
| Medicare | 2 | 2023 | 902 | 0.090 |
Why?
|
| Thinness | 1 | 2012 | 99 | 0.090 |
Why?
|
| Beryllium | 1 | 2012 | 161 | 0.080 |
Why?
|
| Morphogenesis | 1 | 2012 | 172 | 0.080 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2015 | 364 | 0.080 |
Why?
|
| Proinsulin | 1 | 2011 | 52 | 0.080 |
Why?
|
| Amine Oxidase (Copper-Containing) | 1 | 2010 | 5 | 0.080 |
Why?
|
| Mexican Americans | 1 | 2012 | 119 | 0.080 |
Why?
|
| Diet, Diabetic | 1 | 2011 | 33 | 0.080 |
Why?
|
| Lactation | 1 | 2012 | 193 | 0.080 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2011 | 38 | 0.080 |
Why?
|
| Lung Diseases | 1 | 2017 | 780 | 0.080 |
Why?
|
| E-Selectin | 1 | 2010 | 61 | 0.080 |
Why?
|
| Photography | 2 | 2021 | 119 | 0.080 |
Why?
|
| Dietary Sucrose | 1 | 2011 | 50 | 0.080 |
Why?
|
| Voluntary Health Agencies | 2 | 2000 | 6 | 0.080 |
Why?
|
| Insulin Antibodies | 1 | 2011 | 103 | 0.080 |
Why?
|
| Respiratory Function Tests | 2 | 2026 | 543 | 0.080 |
Why?
|
| Self Care | 1 | 2013 | 388 | 0.080 |
Why?
|
| Iron | 2 | 2023 | 357 | 0.080 |
Why?
|
| HLA-DR Antigens | 2 | 2009 | 220 | 0.080 |
Why?
|
| Metabolic Equivalent | 1 | 2010 | 3 | 0.080 |
Why?
|
| Sweetening Agents | 1 | 2011 | 57 | 0.080 |
Why?
|
| Genetic Association Studies | 3 | 2021 | 367 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2026 | 8318 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 2 | 2016 | 1039 | 0.080 |
Why?
|
| Milk, Human | 1 | 2012 | 174 | 0.080 |
Why?
|
| World Health Organization | 2 | 2000 | 104 | 0.080 |
Why?
|
| Berylliosis | 1 | 2012 | 202 | 0.080 |
Why?
|
| Topography, Medical | 1 | 2010 | 10 | 0.080 |
Why?
|
| Video Games | 1 | 2010 | 30 | 0.080 |
Why?
|
| Glucose Clamp Technique | 1 | 2010 | 199 | 0.080 |
Why?
|
| Glycosuria | 1 | 2009 | 10 | 0.080 |
Why?
|
| Pulsatile Flow | 1 | 2010 | 61 | 0.080 |
Why?
|
| Hypolipidemic Agents | 1 | 2010 | 89 | 0.080 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2025 | 571 | 0.080 |
Why?
|
| Sensitivity and Specificity | 4 | 2026 | 1995 | 0.080 |
Why?
|
| Cell Adhesion Molecules | 1 | 2010 | 181 | 0.080 |
Why?
|
| Neoplasms | 1 | 2025 | 2900 | 0.080 |
Why?
|
| Exercise Test | 1 | 2012 | 626 | 0.080 |
Why?
|
| Stochastic Processes | 1 | 2009 | 65 | 0.070 |
Why?
|
| Elasticity | 1 | 2010 | 189 | 0.070 |
Why?
|
| Arm | 1 | 2010 | 110 | 0.070 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2018 | 1174 | 0.070 |
Why?
|
| Models, Theoretical | 2 | 2025 | 556 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 968 | 0.070 |
Why?
|
| Consensus | 2 | 2022 | 478 | 0.070 |
Why?
|
| Mortality | 1 | 2011 | 378 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 527 | 0.070 |
Why?
|
| Limit of Detection | 2 | 2021 | 92 | 0.070 |
Why?
|
| Genetic Carrier Screening | 1 | 2008 | 32 | 0.070 |
Why?
|
| Reproductive History | 1 | 2008 | 12 | 0.070 |
Why?
|
| Blood Flow Velocity | 1 | 2010 | 420 | 0.070 |
Why?
|
| Menopause | 1 | 2011 | 326 | 0.070 |
Why?
|
| Leg | 1 | 2010 | 242 | 0.070 |
Why?
|
| Endothelium, Vascular | 1 | 2014 | 955 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2025 | 1742 | 0.070 |
Why?
|
| Pregnancy in Adolescence | 1 | 2008 | 82 | 0.070 |
Why?
|
| HLA-DQ Antigens | 1 | 2008 | 174 | 0.060 |
Why?
|
| Forecasting | 1 | 2009 | 388 | 0.060 |
Why?
|
| Cell Differentiation | 3 | 2023 | 2040 | 0.060 |
Why?
|
| Receptors, Drug | 1 | 2007 | 10 | 0.060 |
Why?
|
| Feasibility Studies | 3 | 2017 | 1109 | 0.060 |
Why?
|
| International Classification of Diseases | 2 | 2021 | 149 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2010 | 252 | 0.060 |
Why?
|
| Health Personnel | 1 | 2013 | 749 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2011 | 671 | 0.060 |
Why?
|
| Quality of Health Care | 1 | 2011 | 692 | 0.060 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 117 | 0.060 |
Why?
|
| Sulfonic Acids | 1 | 2025 | 14 | 0.060 |
Why?
|
| Potassium Channels | 1 | 2007 | 147 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2021 | 1706 | 0.060 |
Why?
|
| Diet, Reducing | 2 | 2017 | 91 | 0.060 |
Why?
|
| Decanoic Acids | 1 | 2025 | 12 | 0.060 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2006 | 44 | 0.060 |
Why?
|
| Contraception | 1 | 2008 | 170 | 0.060 |
Why?
|
| Cameroon | 1 | 2025 | 8 | 0.060 |
Why?
|
| Oxidation-Reduction | 2 | 2021 | 1066 | 0.060 |
Why?
|
| Spirometry | 1 | 2026 | 233 | 0.060 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2025 | 10 | 0.060 |
Why?
|
| Transcription Factors | 2 | 2024 | 1731 | 0.060 |
Why?
|
| Sex Distribution | 3 | 2019 | 386 | 0.060 |
Why?
|
| Gene Frequency | 2 | 2019 | 484 | 0.060 |
Why?
|
| Africa South of the Sahara | 1 | 2025 | 54 | 0.060 |
Why?
|
| Vital Capacity | 1 | 2026 | 292 | 0.060 |
Why?
|
| Seasons | 2 | 2023 | 538 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2011 | 1488 | 0.060 |
Why?
|
| Homeodomain Proteins | 2 | 2021 | 522 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2006 | 294 | 0.060 |
Why?
|
| Forced Expiratory Volume | 1 | 2026 | 450 | 0.050 |
Why?
|
| Cause of Death | 2 | 2021 | 470 | 0.050 |
Why?
|
| Abdominal Wall | 1 | 2004 | 28 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 530 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2006 | 167 | 0.050 |
Why?
|
| Lysine | 1 | 2007 | 304 | 0.050 |
Why?
|
| Patient Participation | 1 | 2008 | 437 | 0.050 |
Why?
|
| South Africa | 1 | 2025 | 266 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2008 | 907 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2025 | 169 | 0.050 |
Why?
|
| Monte Carlo Method | 1 | 2024 | 147 | 0.050 |
Why?
|
| ARNTL Transcription Factors | 1 | 2023 | 17 | 0.050 |
Why?
|
| Appetitive Behavior | 1 | 2023 | 6 | 0.050 |
Why?
|
| Early Diagnosis | 2 | 2015 | 251 | 0.050 |
Why?
|
| Netherlands | 1 | 2023 | 82 | 0.050 |
Why?
|
| Censuses | 1 | 2023 | 33 | 0.050 |
Why?
|
| Appetite Regulation | 1 | 2023 | 31 | 0.050 |
Why?
|
| Alkanesulfonates | 1 | 2023 | 6 | 0.050 |
Why?
|
| Academic Success | 1 | 2023 | 30 | 0.050 |
Why?
|
| Child Care | 1 | 2023 | 36 | 0.050 |
Why?
|
| Carboxylic Acids | 1 | 2023 | 31 | 0.050 |
Why?
|
| Environmental Health | 1 | 2023 | 40 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 376 | 0.050 |
Why?
|
| Hypertrophy | 1 | 2023 | 128 | 0.050 |
Why?
|
| Nitrobenzenes | 1 | 2022 | 15 | 0.050 |
Why?
|
| Remission Induction | 1 | 2004 | 306 | 0.050 |
Why?
|
| Autoantigens | 1 | 2006 | 427 | 0.050 |
Why?
|
| Environment Design | 1 | 2023 | 27 | 0.050 |
Why?
|
| Mitochondria | 2 | 2021 | 992 | 0.050 |
Why?
|
| Uric Acid | 1 | 2024 | 167 | 0.050 |
Why?
|
| Magnesium | 1 | 2023 | 156 | 0.050 |
Why?
|
| Sample Size | 1 | 2023 | 121 | 0.050 |
Why?
|
| Dichlorodiphenyl Dichloroethylene | 1 | 2022 | 4 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 85 | 0.050 |
Why?
|
| Gender Identity | 1 | 2023 | 128 | 0.050 |
Why?
|
| Memory, Short-Term | 1 | 2025 | 267 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1506 | 0.050 |
Why?
|
| Africa, Northern | 1 | 2021 | 4 | 0.040 |
Why?
|
| Coronary Angiography | 1 | 2004 | 328 | 0.040 |
Why?
|
| Tobacco Smoking | 1 | 2022 | 26 | 0.040 |
Why?
|
| Middle East | 1 | 2021 | 18 | 0.040 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 946 | 0.040 |
Why?
|
| Cytosine | 1 | 2022 | 49 | 0.040 |
Why?
|
| Sodium | 1 | 2023 | 198 | 0.040 |
Why?
|
| Disease Susceptibility | 2 | 2015 | 343 | 0.040 |
Why?
|
| Guanine | 1 | 2022 | 85 | 0.040 |
Why?
|
| Adolescent Health | 1 | 2022 | 37 | 0.040 |
Why?
|
| Adipocytes | 1 | 2023 | 223 | 0.040 |
Why?
|
| Phosphocreatine | 1 | 2021 | 44 | 0.040 |
Why?
|
| Metabolic Flux Analysis | 1 | 2021 | 8 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2023 | 227 | 0.040 |
Why?
|
| Amino Acid Substitution | 2 | 2012 | 302 | 0.040 |
Why?
|
| Recurrence | 1 | 2025 | 1134 | 0.040 |
Why?
|
| Isomerism | 1 | 2021 | 56 | 0.040 |
Why?
|
| Ascorbic Acid | 1 | 2023 | 184 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2004 | 2767 | 0.040 |
Why?
|
| Social Stigma | 1 | 2024 | 172 | 0.040 |
Why?
|
| KCNQ1 Potassium Channel | 1 | 2021 | 8 | 0.040 |
Why?
|
| Mutation, Missense | 2 | 2017 | 335 | 0.040 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2021 | 17 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2023 | 529 | 0.040 |
Why?
|
| Phosphates | 1 | 2022 | 177 | 0.040 |
Why?
|
| Diastole | 1 | 2021 | 146 | 0.040 |
Why?
|
| Epidemiologic Methods | 2 | 2013 | 91 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2026 | 1216 | 0.040 |
Why?
|
| Protein Interaction Mapping | 1 | 2021 | 105 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2005 | 517 | 0.040 |
Why?
|
| Maternal Inheritance | 1 | 2020 | 15 | 0.040 |
Why?
|
| Australia | 1 | 2021 | 287 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2021 | 174 | 0.040 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 33 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2021 | 153 | 0.040 |
Why?
|
| Confidence Intervals | 3 | 2008 | 330 | 0.040 |
Why?
|
| Schools | 1 | 2023 | 448 | 0.040 |
Why?
|
| Fathers | 1 | 2000 | 53 | 0.040 |
Why?
|
| Western World | 1 | 2019 | 7 | 0.040 |
Why?
|
| Community Health Services | 1 | 2021 | 231 | 0.040 |
Why?
|
| Severity of Illness Index | 3 | 2014 | 2928 | 0.040 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2020 | 118 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 103 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2021 | 591 | 0.040 |
Why?
|
| Heart | 1 | 2023 | 626 | 0.040 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2019 | 17 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2021 | 1048 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2023 | 494 | 0.040 |
Why?
|
| Hyperphagia | 1 | 2019 | 38 | 0.040 |
Why?
|
| Health Services Research | 1 | 2021 | 391 | 0.040 |
Why?
|
| Norway | 1 | 2018 | 41 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2021 | 499 | 0.040 |
Why?
|
| Social Support | 1 | 2023 | 645 | 0.030 |
Why?
|
| Environmental Monitoring | 1 | 2021 | 346 | 0.030 |
Why?
|
| Environmental Pollution | 1 | 2018 | 20 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 438 | 0.030 |
Why?
|
| Pregnancy Trimester, First | 1 | 2018 | 138 | 0.030 |
Why?
|
| Walking | 1 | 2023 | 542 | 0.030 |
Why?
|
| Fruit | 2 | 2011 | 146 | 0.030 |
Why?
|
| International Cooperation | 1 | 2018 | 197 | 0.030 |
Why?
|
| Bifidobacterium | 1 | 2017 | 21 | 0.030 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2017 | 32 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2017 | 4 | 0.030 |
Why?
|
| Genes, rRNA | 1 | 2017 | 38 | 0.030 |
Why?
|
| Hospitalization | 1 | 2008 | 2458 | 0.030 |
Why?
|
| Electron Transport | 1 | 2017 | 110 | 0.030 |
Why?
|
| Software | 1 | 2023 | 678 | 0.030 |
Why?
|
| Insulin Infusion Systems | 1 | 2022 | 478 | 0.030 |
Why?
|
| Ganglionectomy | 1 | 1997 | 2 | 0.030 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2017 | 49 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2018 | 320 | 0.030 |
Why?
|
| Carnitine | 1 | 2017 | 91 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2018 | 265 | 0.030 |
Why?
|
| Immunoglobulin A | 1 | 2018 | 214 | 0.030 |
Why?
|
| Mitochondrial Diseases | 1 | 2017 | 92 | 0.030 |
Why?
|
| Thoracoscopy | 1 | 1997 | 60 | 0.030 |
Why?
|
| Birth Rate | 1 | 2016 | 31 | 0.030 |
Why?
|
| Sirtuin 1 | 1 | 2016 | 34 | 0.030 |
Why?
|
| ROC Curve | 2 | 2013 | 617 | 0.030 |
Why?
|
| Clinical Coding | 1 | 2016 | 27 | 0.030 |
Why?
|
| Accelerometry | 1 | 2016 | 118 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2008 | 2377 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2015 | 74 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2017 | 218 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 156 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2015 | 54 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 708 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 781 | 0.030 |
Why?
|
| Ankle Brachial Index | 1 | 2015 | 41 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2015 | 48 | 0.030 |
Why?
|
| Palmitic Acid | 1 | 2015 | 40 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2017 | 396 | 0.030 |
Why?
|
| Linoleic Acid | 1 | 2015 | 44 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2019 | 540 | 0.030 |
Why?
|
| International Agencies | 1 | 2014 | 30 | 0.030 |
Why?
|
| Fatty Acid Desaturases | 1 | 2015 | 31 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 1138 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 472 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2015 | 105 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2015 | 250 | 0.030 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2014 | 31 | 0.030 |
Why?
|
| CD40 Antigens | 1 | 2015 | 90 | 0.030 |
Why?
|
| Adolescent Medicine | 1 | 2014 | 26 | 0.030 |
Why?
|
| Fetus | 1 | 2019 | 804 | 0.030 |
Why?
|
| Vitamin E | 1 | 2015 | 125 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 483 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2014 | 50 | 0.030 |
Why?
|
| Carbohydrates | 1 | 2014 | 66 | 0.030 |
Why?
|
| Focus Groups | 1 | 2017 | 569 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2014 | 98 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 847 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1079 | 0.030 |
Why?
|
| Physical Endurance | 1 | 2015 | 276 | 0.030 |
Why?
|
| Mice | 2 | 2023 | 18303 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2803 | 0.030 |
Why?
|
| Forearm | 1 | 2014 | 141 | 0.030 |
Why?
|
| Estradiol | 1 | 2017 | 512 | 0.030 |
Why?
|
| Zinc Transporter 8 | 1 | 2014 | 70 | 0.030 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2013 | 57 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2015 | 202 | 0.020 |
Why?
|
| Amino Acids | 1 | 2017 | 519 | 0.020 |
Why?
|
| Population Groups | 1 | 2013 | 56 | 0.020 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2013 | 39 | 0.020 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2013 | 37 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2017 | 943 | 0.020 |
Why?
|
| Population Growth | 1 | 2012 | 12 | 0.020 |
Why?
|
| Docosahexaenoic Acids | 1 | 2013 | 88 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2014 | 1415 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2013 | 360 | 0.020 |
Why?
|
| Informed Consent | 1 | 2014 | 198 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 1058 | 0.020 |
Why?
|
| Static Electricity | 1 | 2012 | 114 | 0.020 |
Why?
|
| Placebos | 1 | 2012 | 193 | 0.020 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2012 | 65 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 407 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2014 | 514 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2019 | 3114 | 0.020 |
Why?
|
| Athletes | 1 | 2015 | 421 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2015 | 409 | 0.020 |
Why?
|
| Milk | 1 | 2012 | 119 | 0.020 |
Why?
|
| Mammary Glands, Animal | 1 | 2012 | 128 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 2026 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2014 | 396 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2012 | 283 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2017 | 1351 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2013 | 862 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1763 | 0.020 |
Why?
|
| Small-Area Analysis | 1 | 2010 | 6 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2012 | 891 | 0.020 |
Why?
|
| Fetal Weight | 1 | 2009 | 53 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 866 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 506 | 0.020 |
Why?
|
| Skin | 1 | 2014 | 753 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 1365 | 0.020 |
Why?
|
| Intestines | 1 | 2012 | 354 | 0.020 |
Why?
|
| Women's Health | 1 | 2011 | 314 | 0.020 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2011 | 260 | 0.020 |
Why?
|
| Gravidity | 1 | 2008 | 7 | 0.020 |
Why?
|
| Coitus | 1 | 2008 | 24 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 307 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 2588 | 0.020 |
Why?
|
| Psychology, Adolescent | 1 | 2008 | 61 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2008 | 84 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2009 | 290 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 4142 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2010 | 323 | 0.020 |
Why?
|
| Contraception Behavior | 1 | 2008 | 108 | 0.020 |
Why?
|
| Counseling | 1 | 2010 | 400 | 0.020 |
Why?
|
| Bias | 1 | 2008 | 197 | 0.020 |
Why?
|
| Contraceptive Agents, Female | 1 | 2008 | 80 | 0.020 |
Why?
|
| Fertility | 1 | 2008 | 173 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 1993 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2012 | 1115 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2008 | 535 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 279 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 2235 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2012 | 717 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2008 | 429 | 0.010 |
Why?
|
| Waist-Hip Ratio | 1 | 2004 | 37 | 0.010 |
Why?
|
| Radiography, Abdominal | 1 | 2004 | 44 | 0.010 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 919 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2008 | 2057 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2014 | 1725 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 1763 | 0.010 |
Why?
|
| Thoracoscopes | 1 | 1997 | 2 | 0.010 |
Why?
|
| Thromboangiitis Obliterans | 1 | 1997 | 2 | 0.010 |
Why?
|